Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (March 2023)
24 slides from Valion Bio's investor presentation, Mar 31, 2023
Slide 1: Investor Presentation March 2023
NASDAQ TIVC INVESTOR PRESENTATION 2022 SEPT Make text into real text. Use vector graphic for logo. 72? Or 150? The future of medicine is electronic. NASDAQ TIVC INVESTOR PRESENTATION 2023 March
Slide 2: Forward-looking statements
This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. Statements regarding our future results of operations and financial position, economic performance, business strategy and
Slide 3: Investment Highlights
Investment Highlights TIVIC HEALTH Commercial-stage company in high-growth, emerging market: Bioelectronic Medicine. Built with vision to become a market leader in clinically validated, non-invasive bioelectronic therapeutics. Projected to grow at 35% CAGR.1 FDA-approved, award-winning product in ma
Slide 4: The Big Idea
THE BIG IDEA The body is an electrochemical system. Bioelectronic medicine restores health by tuning body’s innate electrical signals. 4 Bioelectronic medicine represents a multi-billion-dollar opportunity and has the “potential to become a pillar of medical treatment.” Bioelectronics ‘jump-start th
Slide 5: Moving from Implants to Non-invasive
IMPLANTS NON-INVASIVE Moving from Implants to Non-invasive BIOELECTRONICS TRAJECTORY 1960s Pacemakers 2010s Sleep Apnea 1990s Deep Brain, Spinal Cord Bioelectronics historically implanted technology. Tivic Health tunes signals non-invasively. Strong safety profiles, broader applicability, emerging a
Slide 6: Bioelectronic Platform for Non-invasive Peripheral Nerve Stimulation
BIOELECTRONIC PLATFORM FOR Non-invasive Peripheral Nerve Stimulation Programmable Parameters Proprietary Algorithms Patented Form Factor produces varied biological responses for different diseases and conditions enables low-level electrical current to penetrate deeply through tissue detects optimal
Slide 7: Common Platform, Multiple Opportunities
COMMON PLATFORM, MULTIPLE OPPORTUNITIES Active Clinical Pipeline 7 NASDAQ: TIVC TIVICHEALTH.COM 600K US adults annually3 39M US adults: up to 1B globally4 * Investigational use only (1) Data from publicly available information (that has not been independently verified by the company) combined with c
Slide 8: Clears Congestion, Relieves Sinus Pain
CLEARS CONGESTION, RELIEVES SINUS PAIN FDA-approved and CE-marked Proven in double-blind RCT @ Stanford Medical Center $169 MSRP $11.1B sinus, cold & allergy sector, dominated by pharmaceuticals1 90% of sinus sufferers want to reduce use of pharmaceuticals2 82% prefer ClearUP to current treatments3
Slide 9: Market Landscape
Decongestants Antihistamines Not effective for congestion and pain Headache, sleepiness, fatigue, dry mouth, and sore throat Oral and intranasal Insomnia, nervousness, heart palpitations, headache, sweating, nausea, trembling, weakness, rebound Daily Saline Irrigation Most commonly recommended optio
Slide 10: Dual Mechanisms of Action
Dual Mechanisms of Action BASED ON SCIENCE OF NEUROMODULATION Trigeminal nerve mediates pain relief1 Sympathetic nerves induce vasoconstriction2-5 * References for footnotes 1-11 are on appendix slide 23. ClearUP has been proven effective in treating sinus and nasal inflammatory conditions. Other in
Slide 11: Fast-acting: double-blind randomized trial results
Maul XA, Borchard NA, Hwang PH, Nayak JV. Microcurrent technology for rapid relief of sinus pain: a randomized, placebo‐controlled, double‐blinded clinical trial. Int Forum Allergy Rhinol. 2019;9:352–356. Fast-acting Double-blind, randomized, sham-controlled trial examined acute response. Reduction
Slide 12: Continued improvement with regular use
Goldsobel, A.B., Prabhakar, N. & Gurfein, B.T. Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion. Bioelectron Med 5, 18 (2019) doi:10.1186/s42234-019-0035-x #p < 0.01; *p < 0.0001; two-tailed paired t-test comparing pre-treatme
Slide 13: Robust Foundations
K182025 CE 704687 DEN200006 ISSUED PATENTS 96 issued claims 5 PATENTS PENDING 21 STRONG INTELLECTUAL PROPERTY THREE REGULATORY CLEARANCES PEER-REVIEWED PUBLICATIONS Open-label 4-week study. Published: Bioelectronic Medicine Double-blind, sham-controlled, randomized trial. Published: International Fo
Slide 14: Large Markets, Significant Growth Opportunity
$11.1B1 Large Markets, Significant Growth Opportunity MARKET SIZE $8BE US TAM2 Allergy, Sinusitis, Cold & Flu, + OTC Sinus Care US Market (1) Data from Mintel Group Ltd. (2) Data from publicly available information (that has not been independently verified by the company) combined with company spons
Slide 15: Expanding the Growth Engine
broad, existing CE Mark provides global clearance New Indications breathing ease (US) Connected Device • Subscription app • New business models In-store Distribution Sinus Pain, Pressure Congestion from any cause (US) Device w/data augmentation HCP referrals Sinus Pain from allergies (2019) Device O
Slide 16: Structured Approach to Growth
Structured Approach to Growth MARKET DEVELOPMENT Product development FDA clearance Market introduction Build credibility & traction Harden and grow ecommerce Expand target segments Extend ClearUP product line Build healthcare professional (HCP) engagement 2016 – 2021 2022 2023-2024 2024 – 2026+ New
Slide 17: Experienced, Execution-oriented Leadership
Experienced, Execution-oriented Leadership LEADERSHIP TEAM Jennifer Ernst Chief Executive Officer, MBA Founded and built Tivic Health from founding to IPO in 5 years. Took prior company (Thin Film Electronics) from 8-person R&D team to $480MM market cap in < 5 years, as CEO of US subsidiary. Blake G
Slide 18: Operating Results
Twelve Months Ended December 31 (in thousands) FY 2022 FY 2021 Revenues $ 1,840 $ 1,257 Gross Profit (Loss) 299 (38) Net loss (10,096) (8,494) Operating Results FINANCIALS 46% 2022 vs 2021 highlights Revenues increased 46% YOY Direct-to-consumer revenue increased 114% YOY Gross Margin improved ~9X(1
Slide 19: Capitalization Table
Capitalization Table FINANCIALS March 24, 2023 Common Stock 29,677,734 Options (WAEP: $2.01) 1,248,850 Warrants (WAEP: $1.18) 1,272,680 Fully Diluted Shares 32,199,264
Slide 20: Financial Position
Financial Position FINANCIALS (in thousands) December 31, 2022 Cash and Cash Equivalents $ 3,517 Total Assets 5,856 Total Liabilities 2,226 Total Stockholders’ Equity $ 3,630 Clean balance sheet No debt Raised $5M in equity financing in Feb 2023
Slide 21: Investor Summary
Investor Summary HIGHLIGHTS FDA-cleared products in high-growth sector. Large available market $8B1 in US; global opportunity. Established Tier 1 channels growing. Regulatory clearances for both US and international sales. Robust IP portfolio, recently issued patents. Clinical validation with leadin
Slide 22: Jennifer Ernst, CEO
Jennifer Ernst CEO, Tivic Health ir@tivichealth.com
Slide 23: Dual Mechanisms of Action (Appendix)
Dual Mechanisms of Action APPENDIX Trigeminal nerve mediates pain relief1 Sympathetic nerves induce vasoconstriction2-5 More than a sinus treatment ClearUP has been proven effective in treating sinus and nasal inflammatory conditions. Other inflammatory conditions associated with nerve activity in t
Slide 24: Slide 24
Tivic Health Systems — Investor Presentation (March 2023) on 6ix